EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenicity of a Recombinant MVA Vector Vaccine Expressing the Prefusion RSV F Protein in Balb/c Mice

Jinhui Miao, Min Liu, Qun Zhang, Feixia Gao, Yongshan Zheng, Cheng He

Vaccines · 31.03.2026 · 14 (4) · 317

DOI: 10.3390/vaccines14040317 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 31.03.2026. Verfasst von Jinhui Miao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Biological Products, Shanghai 200051, China. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections and poses a substantial disease burden to infants, older adults, and immunocompromised populations.

Methods

In this study, a recombinant vaccinia virus (rMVA-RSV preF) was constructed based on the modified vaccinia virus Ankara (MVA) platform by inserting a stabilized prefusion F protein gene of RSV into the MVA genome. The immunogenicity of rMVA-RSV preF and preF protein was evaluated in Balb/c mice under different vaccination regimens.

Results

A heterologous prime–boost regimen, priming with rMVA-RSV preF and boosting with AS01E-adjuvanted preF protein, elicited robust cellular and humoral immune responses with a Th1 bias. This regimen significantly enhanced immunogenicity compared to homologous vaccination.

Conclusions

There is a lack of data from further challenge studies to support the efficacy of the rMVA-RSV preF vaccine in terms of protection, but our findings demonstrate a favorable immunogenicity profile of the rMVA-RSV preF vaccine, supporting its further development as a promising RSV vaccine candidate.

Schlagwörter

Stichwörter der Autor:innen

MVARSVheterologous prime–boost regimenimmunogenicityprefusion F proteinvaccine

Autor:innen und Institutionen

  • Shanghai Institute of Biological Products, Shanghai 200051, China.
  • State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing 100024, China.

Förderung

  • National Key Research and Development Program, China

Zitieren

APA

Miao, J., Liu, M., Zhang, Q., Gao, F., Zheng, Y., & He, C. (2026). Immunogenicity of a Recombinant MVA Vector Vaccine Expressing the Prefusion RSV F Protein in Balb/c Mice. Vaccines, 14(4), 317. https://doi.org/10.3390/vaccines14040317

Vancouver

Miao J, Liu M, Zhang Q, Gao F, Zheng Y, He C. Immunogenicity of a Recombinant MVA Vector Vaccine Expressing the Prefusion RSV F Protein in Balb/c Mice. Vaccines. 2026;14(4):317. doi:10.3390/vaccines14040317

BibTeX
@article{Miao2026,
  author = {Miao, Jinhui and Liu, Min and Zhang, Qun and Gao, Feixia and Zheng, Yongshan and He, Cheng},
  title = {Immunogenicity of a Recombinant MVA Vector Vaccine Expressing the Prefusion RSV F Protein in Balb/c Mice},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {4},
  pages = {317},
  doi = {10.3390/vaccines14040317}
}
Kostenlos starten →